Is HER2/neu expressed in nonepithelial ovarian malignancies?

[1] Slamon D.J., Leyland-Jones B., Shak S., Et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, pp. 783-792, (2001)

[2] Slamon D.J., Godolphin W., Jones L.A., Et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244, pp. 707-712, (1989)

[3] Peethambaran P.P., Clibee W.A., Lubiniecki G., Et al., Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy, Gynecol Oncol, 89, pp. 99-104, (2003)

[4] Berchuck A., Kamel A., Whitaker R., Et al., Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer, Cancer Res, 50, pp. 4087-4091, (1990)

[5] Rubin S.C., Finstad C.L., Wong G.Y., Almadrones L., Plante M., Lloyd K.O., Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis, Am J Obstet Gynecol, 168, pp. 162-169, (1993)

[6] Rubin S.C., Finstad C.L., Federici M.G., Scheiner L., Lloyd K.O., Hoskins W.J., Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer, Cancer, 73, pp. 1456-1459, (1994)

[7] Hogdall E.V., Christensen L., Kjaer S.K., Et al., Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study, Cancer, 98, pp. 66-73, (2003)

[8] Camilleri-Broet S., Hardy-Bessard A.C., Le Tourneau A., HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group, Ann Oncol, 15, pp. 104-112, (2004)

[9] Lee C.H., Huntsman D.G., Cheang M.C., Et al., Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma, Int J Gynecol Pathol, 24, pp. 147-152, (2005)

[10] Verri E., Guglielmini P., Puntoni M., Et al., HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study, Oncology, 68, pp. 154-161, (2005)

[1] Slamon D.J., Leyland-Jones B., Shak S., Et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, pp. 783-792, (2001)

[2] Slamon D.J., Godolphin W., Jones L.A., Et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244, pp. 707-712, (1989)

[3] Peethambaran P.P., Clibee W.A., Lubiniecki G., Et al., Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy, Gynecol Oncol, 89, pp. 99-104, (2003)

[4] Berchuck A., Kamel A., Whitaker R., Et al., Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer, Cancer Res, 50, pp. 4087-4091, (1990)

[5] Rubin S.C., Finstad C.L., Wong G.Y., Almadrones L., Plante M., Lloyd K.O., Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis, Am J Obstet Gynecol, 168, pp. 162-169, (1993)

[6] Rubin S.C., Finstad C.L., Federici M.G., Scheiner L., Lloyd K.O., Hoskins W.J., Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer, Cancer, 73, pp. 1456-1459, (1994)

[7] Hogdall E.V., Christensen L., Kjaer S.K., Et al., Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study, Cancer, 98, pp. 66-73, (2003)

[8] Camilleri-Broet S., Hardy-Bessard A.C., Le Tourneau A., HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group, Ann Oncol, 15, pp. 104-112, (2004)

[9] Lee C.H., Huntsman D.G., Cheang M.C., Et al., Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma, Int J Gynecol Pathol, 24, pp. 147-152, (2005)

[10] Verri E., Guglielmini P., Puntoni M., Et al., HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study, Oncology, 68, pp. 154-161, (2005)